Add this topic to your myFT Digest for news straight to your inbox
Critics fear Silicon Valley lobbying has weakened the defence of intellectual property and sapped innovation
Deal to exchange 400,000 compounds highlights pharma groups’ increasing willingness to collaborate
Pharma groups switch to ‘core’ earnings, excluding many charges
The great-grandson of drugmaker’s founder discusses corporate governance and M&A
The new head of the Swiss drugs group is adopting a different leadership style
My interest in GW pharmaceuticals has been reawakened, writes Kevin Goldstein-Jackson
International Edition